FY2026 EPS Estimate for Connect Biopharma Lifted by Analyst

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB – Free Report) – Investment analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Connect Biopharma in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($1.11) for the year, up from their prior estimate of ($1.17). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Connect Biopharma’s FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($1.05) EPS and FY2030 earnings at ($1.11) EPS.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partners began coverage on shares of Connect Biopharma in a research note on Monday, October 12th. They issued an “outperform” rating and a $4.00 price target on the stock. Weiss Ratings cut shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Canaccord Genuity Group reiterated a “buy” rating on shares of Connect Biopharma in a report on Tuesday. Wall Street Zen downgraded shares of Connect Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Finally, Oppenheimer cut their target price on Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $5.88.

Check Out Our Latest Research Report on Connect Biopharma

Connect Biopharma Price Performance

Shares of CNTB opened at $0.67 on Thursday. Connect Biopharma has a 1-year low of $0.55 and a 1-year high of $3.82. The stock has a market cap of $41.89 million, a PE ratio of -0.58 and a beta of 0.06. The firm has a 50-day simple moving average of $0.96 and a two-hundred day simple moving average of $2.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.12 million.

Hedge Funds Weigh In On Connect Biopharma

Institutional investors have recently bought and sold shares of the company. BML Capital Management LLC increased its stake in Connect Biopharma by 574.1% during the third quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock worth $4,251,000 after purchasing an additional 3,291,113 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Connect Biopharma during the first quarter worth about $1,945,000. Knott David M Jr lifted its position in shares of Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Connect Biopharma by 12.0% during the third quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock worth $414,000 after purchasing an additional 40,387 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in shares of Connect Biopharma in the first quarter valued at approximately $41,000. 58.72% of the stock is owned by institutional investors and hedge funds.

About Connect Biopharma

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

See Also

Earnings History and Estimates for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.